Who are NovaBridge Biosciences's main suppliers?

NovaBridge Biosciences (NBP) key suppliers include: CONTRACT-MANUFACTURERS, CRITICAL-REAGENT-SUPPLIERS, THIRD-PARTIES, CHINA-BASED-SUPPLIERS. View the full supplier network at chainsifter.com/chain/NBP.

Who are NovaBridge Biosciences's major customers?

NovaBridge Biosciences (NBP) key customers include: Abbott Laboratories, Abbott Laboratories, Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, Bristol-Myers Squibb Co and 25 more. View the full customer network at chainsifter.com/chain/NBP.

What sector is NovaBridge Biosciences in?

NovaBridge Biosciences (NBP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NovaBridge Biosciences Supplier List (NBP): 4 Verified Suppliers

4Suppliers

30Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

NovaBridge Biosciences (NBP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

40Total relationships

1Distinct source URLs

8High confidence

0.729Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

NovaBridge Biosciences Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURERS	CONTRACT-MANUFACTURERS	90%	We rely on third parties, including those located in China, for supply of our drug candidates, and our strategy is to outsource all manufacturing of our drug candidates and products to third parties.
CRITICAL-REAGENT-SUPPLIERS	CRITICAL-REAGENT-SUPPLIERS	90%	We rely on third parties, including those located in China, for supply of our drug candidates, and our strategy is to outsource all manufacturing of our drug candidates and products to third parties.
THIRD-PARTIES	THIRD-PARTIES	90%	We also rely on third parties, including those located in China, for supply of our drug candidates, and our strategy is to outsource all manufacturing of our drug candidates and products to third parties.
CHINA-BASED-SUPPLIERS	CHINA-BASED-SUPPLIERS	80%	In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could re…

NovaBridge Biosciences Customers

Ticker	Name	Confidence	Evidence
ABT	Abbott Laboratories	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
ABT	Abbott Laboratories	72%	Reciprocal relationship from ABT graph: Reciprocal relationship from NBP graph: Reciprocal relationship from ABT graph: Reciprocal relationship from NBP graph: Reciprocal relationship from ABT graph:…
BMY	Bristol-Myers Squibb Company	72%	roduction, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems inc…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from NBP graph: Reciprocal relationship from BMY graph: Reciprocal relationship from NBP graph: roduction, particularly in scaling up o…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from NBP graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from NBP graph: roduction, particularly in scaling …
BMYMP	Bristol-Myers Squibb Co	72%	roduction, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems inc…
EH	EHang Holdings Limited	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
EH	EHang Holdings Limited	72%	Reciprocal relationship from EH graph: Reciprocal relationship from NBP graph: Reciprocal relationship from EH graph: Reciprocal relationship from NBP graph: Reciprocal relationship from EH graph: Re…
EM	Smart Share Global Limited	72%	Reciprocal relationship from EM graph: Reciprocal relationship from NBP graph: rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic tra…
EM	Smart Share Global Limited	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from NBP graph: rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic tr…
JNJ	Johnson & Johnson	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
LBRX	LB Pharmaceuticals Inc	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
LBRX	LB Pharmaceuticals Inc	72%	Reciprocal relationship from LBRX graph: Reciprocal relationship from NBP graph: Reciprocal relationship from LBRX graph: Reciprocal relationship from NBP graph: Reciprocal relationship from LBRX gra…
NMRA	Neumora Therapeutics, Inc.	72%	Reciprocal relationship from NMRA graph: Reciprocal relationship from NBP graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from NBP graph: Reciprocal relationship from NMRA gra…
NMRA	Neumora Therapeutics, Inc.	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
PRE	Prenetics Global Limited	72%	Reciprocal relationship from PRE graph: Reciprocal relationship from NBP graph: Reciprocal relationship from PRE graph: Reciprocal relationship from NBP graph: Reciprocal relationship from PRE graph:…
PRE	Prenetics Global Limited	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
SBMFF	SBMFF	72%	Reciprocal relationship from SBMFF graph: Reciprocal relationship from NBP graph: rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic …
SBMFF	SBMFF	72%	rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products. The following table sets forth a su…
SNYNF	Sanofi	72%	itures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain ad…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from NBP graph: itures and undertake development or commercialization activities at our own expense. If we elect to fund and undertak…
ABBV	AbbVie Inc.	62%	Reciprocal relationship from ABBV graph: Reciprocal relationship from NBP graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from NBP graph: roduction, particularly in scaling up…
ABBVIE-GLOBAL-ENTERPRISES-LTD	ABBVIE-GLOBAL-ENTERPRISES-LTD	62%	roduction, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems inc…
ABBVIE-IRELAND-UNLIMITED-COMPANY	ABBVIE-IRELAND-UNLIMITED-COMPANY	62%	roduction, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems inc…
I-MAB-BIOPHARMA-CO-LTD	I-MAB-BIOPHARMA-CO-LTD	62%	al statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements an…
I-MAB-BIOPHARMA-HONG-KONG-LIMITED	I-MAB-BIOPHARMA-HONG-KONG-LIMITED	62%	g events is beyond our control but may result in regional or global economic distress, which may materially and adversely affect our business, financial condition and results of operations. We may be…
I-MAB-BIOPHARMA-U-S-LIMITED	I-MAB-BIOPHARMA-U-S-LIMITED	62%	olders). Additionally, an individual U.S. Shareholder with respect to a CFC generally will not be allowed certain tax deductions or foreign tax credits that would be allowed to a corporate U.S. Share…
NANJING-CO-LTD	NANJING-CO-LTD	62%	olders). Additionally, an individual U.S. Shareholder with respect to a CFC generally will not be allowed certain tax deductions or foreign tax credits that would be allowed to a corporate U.S. Share…
SHANGHAI-CO-LTD	SHANGHAI-CO-LTD	62%	al statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements an…

NovaBridge Biosciences Debt Obligations

Instrument	Description	Confidence	Evidence
NBP-DEBT	Debt stack $4.2M	90%	Market cache reports total debt of $4.2M.
NBP-DEBT-11180	Warrants outstanding: 109743000	90%	xbrl warrant detail from xbrl 2021-12-31.
NBP-DEBT-11181	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.

NovaBridge Biosciences Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NovaBridge Biosciences.

NovaBridge Biosciences Ownership

Holder	Name	Confidence	Evidence
NBP-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 49 tracked holders.

NovaBridge Biosciences Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BNRG	Brenmiller Energy Ltd	100.00	2
ALVO	Alvotech	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2

NovaBridge Biosciences Supply Chain